Anti-Choline Acetyltransferase antibody [EPR16590],Abcam,AB178850

Product Specifications Anti-Choline Acetyltransferase antibody [EPR16590] (ab178850) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in IHC-P, WB in guinea pig, mouse, rabbit, rat samples. Anti-Choline Acetyltransferase antibody [EPR16590] (ab178850) specifically detects Choline Acetyltransferase (UniProt ID: P13222; Molecular weight: 72kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL and 1 mL). Quality and Validation Abcam's high quality manufacturing and validation processes ensure Anti-Choline Acetyltransferase antibody [EPR16590] (ab178850) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-Choline Acetyltransferase antibody [EPR16590] (ab178850) has been cited over 54 times in peer reviewed journals and is trusted by the scientific community. Anti-Choline Acetyltransferase antibody [EPR16590] (ab178850) has 5 independent reviews from customers. Related Products Conjugation-ready, carrier free format available for antibody clone EPR16590 - ab221793 . Antibody clone EPR16590 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor® 647, Alexa Fluor® 488, Alexa Fluor® 594, Alexa Fluor® 568, Alexa Fluor® 555, Alexa Fluor® 750 ( ab225262 , ab225263 , ab311819 , ab313102 , ab313295 , ab321220 ). Target Information Choline Acetyltransferase (ChAT) is an enzyme crucial for the synthesis of acetylcholine, a neurotransmitter involved in many functions, including muscle activation and cognitive processes. It serves as a marker for cholinergic neurons in research. Impaired ChAT activity is implicated in various conditions, including Alzheimer's disease (AD), where decreased acetylcholine levels lead to cognitive deficits, and myasthenia gravis, an autoimmune disorder that disrupts neuromuscular communication. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .